Medivation, Inc. (NASDAQ: MDVN) today announced that it has effected a stock dividend on its common stock, in which each outstanding share of common stock received an additional share of common stock.
Medivation’s common stock will begin trading on a post-dividend basis on the NASDAQ Global Select Market at the opening of trading today, September 16, 2015.
About Medivation Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com
Chief Financial Officer
(415) 543-3470Anne Bowdidge
Senior Director, Investor Relations